1. Abdelmegeed, S. M. and Mohammed, S. 2018. Canine mammary tumors as a model for human disease (Review). Oncol. Lett. 15: 8195–8205.
2. Abou Asa, S., Mori, T., Maruo, K., Khater, A., El-sawak, A., Abd el-Aziz, E., Yanai, T. and Sakai, H. 2015. Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours. Vet. Comp. Oncol. 13: 237–245.
3. Abou Asa, S., Murai, A., Murakami, M., Hoshino, Y., Mori, T., Maruo, K., Khater, A., El-sawak, A., Abdo el-Aziz, E., Yanai, T. and Sakai, H. 2012. Expression of platelet-derived gowth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma. Histol. Histopathol. 27: 601–607.
4. Adachi, M., Hoshino, Y., Izumi, Y., Sakai, H. and Takagi, S. 2016. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosar. Can. J. Vet. Res. 80: 209–216.
5. Adams, V. J., Evans, K. M., Sampson, J. and Wood, J. L. N. 2010. Methods and mortality results of a health survey of purebred dogs in the UK. J. Small Anim. Pract. 51: 512–524.
6. Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K. and Walter, P. 2015. Cell death. pp. 1023–1024. In: Molecular biology of the cell, 6th ed., (Wilson, John and Hunt, Tim eds.) Garland Science, New York.
7. Allen, J. E., Crowder, R. and El-Deiry, W. S. 2015. First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent. PLoS One. 10: 1–9.
8. Allen, J. E., Crowder, R. and El-Deiry, W. S. 2016. First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent. PLoS One. 11: 1–1.
9. Allen, J. E., Krigsfeld, G., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E., Scata, K. A., Zhou, J., Wu, G. S. and El-deiry, W. S. 2013. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 5: 1–23.
10. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R. H. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155–162.
11. Batschinski, K., Nobre, A., Vargas-Mendez, E., Tedardi, M. V., Cirillo, J., Cestari, G., Ubukata, R. and Dagli, M. L. Z. 2018. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014). Can. Vet. J. 59: 967–972.
12. Bongiovanni, L., Romanucci, M., Malatesta, D., D’Andrea, A., Ciccarelli, A. and Della Salda, L. 2015. Survivin and related proteins in canine mammary tumors: Immunohistochemical expression. Vet. Pathol. 52: 269–275.
13. Brown NO, Patnaik AK, M. E. 1985. Canine hemangiosarcoma: Retrospective analysis of 104 cases. J Am Vet Med Assoc. 186: 56–58.
14. Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M. N., Gonzalez, R., Clark, J. I., Richart, J. M., Lao, C. D., Tykodi, S. S., Silk, A. W. and McDermott, D. F. 2019. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J. Immunother. Cancer. 7: 1–7.
15. Buchsbaum, D. J., Oliver, P. G., Hammond, C. J., Zhou, T., Zhang, S., Carpenter, M., LoBuglio, A. F. and Grizzle, W. E. 2003. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9: 3731–3741.
16. Burton, J. H., Venable, R. O., Vail, D. M., Williams, L. E., Clifford, C. A., Axiak-Bechtel, S. M., Avery, A. C. and Thamm, D. H. 2015. Pulse-administered toceranib phosphate plus lomustine for treatment of unresectable mast cell tumors in dogs. J. Vet. Intern. Med. 29: 1098–1104.
17. Caceres, S., Monsalve, B., Peña, L., de Andres, P. J., Alonso-Diez, A., Illera, M. J., Woodward, W. A., Reuben, J. M., Silvan, G. and Illera, J. C. 2018. In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines. Vet. Comp. Oncol. 16: 148–158.
18. Carlson, A., Alderete, K. S., Grant, M. K. O., Seelig, D. M., Sharkey, L. C. and Zordoky, B. N. M. 2017. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. Vet. Comp. Oncol. 1–9.
19. Carlsten, K. S., London, C. A., Haney, S., Burnett, R., Avery, A. C. and Thamm, D. H. 2012. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J. Vet. Intern. Med. 26: 1–16.
20. Cheng, A. L., Kang, Y. K., He, A. R., Lim, H. Y., Ryoo, B. Y., Hung, C. H., Sheen, I. S., Izumi, N., Austin, T., Wang, Q., Greenberg, J., Shiratori, S., Beckman, R. A. and Kudo, M. 2015. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. J. Hepatol. 63: 896–904.
21. Chu, L. L., Kong, J. M. C., Ghahremani, M., Schmeing, M., Pelletier, J., Rutteman, G. R., Misdorp, W. and Van Garderen, E. 1998. Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res. Treat. 50: 11–25.
22. Cretney, E., Takeda, K. and Smyth, M. J. 2007. Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int. J. Biochem. Cell Biol. 39: 280–286.
23. Danial, N. N. and Korsmeyer, S. J. 2004. Cell death: Critical control points. Cell. 116: 205–219.
24. De, C. H., Toledo-Piza, E., Amorin, R., Barboza, A. and Tobias, K. M. 2009. Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can. Vet. J. 50: 506–510.
25. Degli-Esposti, M. a, Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. a and Goodwin, R. G. 1997. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet remains an incomplete death domain. Immunity. 7: 813–820.
26. Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G. and Smith, C. A. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186: 1165–1170.
27. Díaz-Vélez, J. C., Ahlers, M., Desiati, P. and Fiorino, D. 2017. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Proc. Sci. 151: 27– 40.
28. Dickerson, E. B., Thomas, R., Fosmire, S. P., Lamerato-Kozicki, A. R., Bianco, S. R., Wojcieszyn, J. W., Breen, M., Helfand, S. C. and Modiano, J. F. 2005. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet. Pathol. 42: 618–632.
29. Dickerson, E. B., Marley, K., Edris, W., Tyner, J. W., Schalk, V., MacDonald, V., Loriaux, M., Druker, B. J. and Helfand, S. C. 2013. Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-β and Src in tumor growth. Transl. Oncol. 6: 158–168.
30. Dobson, J. M., Samuel, S., Milstein, H., Rogers, K. and Wood, J. L. N. 2002. Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. J. Small Anim. Pract. 43: 240–246.
31. Elders, R. C., Baines, S. J. and Catchpole, B. 2009. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Vet. Immunol. Immunopathol. 130: 11– 16.
32. Emery, J. G., Mcdonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., Diprinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C. and Young, P. R. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273: 14363–14367.
33. Eustace, A. J., Conlon, N. T., McDermott, M. S. J., Browne, B. C., O’Leary, P., Holmes, F. A., Espina, V., Liotta, L. A., O’Shaughnessy, J., Gallagher, C., O’Driscoll, L., Rani, S., Madden, S. F., O’Brien, N. A., Ginther, C., Slamon, D., Walsh, N., Gallagher, W. M., Zagozdzon, R., Watson, W. R., O’Donovan, N. and Crown, J. 2018. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 18: 1–14.
34. Fei, H. rong, Yuan, C., Wang, G. ling, Zhao, Y., Li, Z. jun, Du, X. and Wang, F. Z. 2019. Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Phytomedicine. 62: 1–9.
35. Finotello, R., Henriques, J., Sabattini, S., Stefanello, D., Felisberto, R., Pizzoni, S., Ferrari, R. and Marconato, L. 2017. A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma. Vet. Comp. Oncol. 15: 493–503.
36. Floros, T. and Tarhini, A. A. 2015. Anticancer cytokines: Biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42: 539–548.
37. Fukumoto, S., Saida, K., Sakai, H., Ueno, H., Iwano, H. and Uchide, T. 2016. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma. Life Sci. 159: 55–60.
38. Fyfe, G., Fisher, R., Rosenberg, S., Sznol, M., Parkinson, D. and Louie, A. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13: 688–96.
39. Garden, O. A., Volk, S. W., Mason, N. J. and Perry, J. A. 2018. Companion animals in comparative oncology: One Medicine in action. Vet. J. 240: 6–13.
40. GD, R. 2004. Mechanisms of bone metastasis. N Engl j Med. 350: 1655–64.
41. Ghoncheh, M., Pournamdar, Z. and Salehiniya, H. 2016. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pacific J. Cancer Prev. 17: 43–46.
42. Goldschmidt, M. H., Peña, L., Rasotto, R. and Zappulli, V. 2011. Classification and grading of canine mammary tumors. Vet. Pathol. 48: 117–131.
43. Göritz, M., Müller, K., Krastel, D., Staudacher, G., Schmidt, P., Kühn, M., Nickel, R. and Schoon, H. A. 2013. Canine splenic haemangiosarcoma: Influence of metastases, chemotherapy and growth pattern on post-splenectomy survival and expression of angiogenic factors. J. Comp. Pathol. 149: 30–39.
44. Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H. and Kubin, M. Z. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161: 2833–2840.
45. Hansen, K. and Khanna, C. 2004. Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development. Eur. J. Cancer. 40: 858–880.
46. Hayes-Jordan, A. A., Ma, X., Menegaz, B. A., Lamhamedi-Cherradi, S. E., Kingsley, C. V., Benson, J. A., Camacho, P. E., Ludwig, J. A., Lockworth, C. R., Garcia, G. E. and Craig, S. L. 2018. Efficacy of ONC201 in desmoplastic small round cell tumor. Neoplasia (United States). 20: 524–532.
47. Head, K. ., Cullen, J. M., Dubielzig, R. R., Else, R. W., Misdorp, W., Patnaik, A. K., Tateyama, S. and Van der Gaag, I. 2003. Histological classification of tumors of the alimentary system of domestic animals, 2nd ed., Armed Forces institute of pathology, Washington.
48. Heishima, K., Mori, T., Ichikawa, Y., Sakai, H., Kuranaga, Y., Nakagawa, T., Tanaka, Y., Okamura, Y., Masuzawa, M., Sugito, N., Murakami, M., Yamada, N., Akao, Y. and Maruo, K. 2015. MicroRNA-214 and microRNA-126 are potential biomarkers for malignant endothelial proliferative diseases. Int. J. Mol. Sci. 16: 25377–25391.
49. Heishima, K., Mori, T., Sakai, H., Sugito, N., Murakami, M., Yamada, N., Akao, Y. and Maruo, K. 2015. MicroRNA-214 promotes apoptosis in canine hemangiosarcoma by targeting the COP1-p53 axis. PLoS One. 10: 1–19.
50. HellmÉn, E. 1992. Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines. Vitr. Cell. Dev. Biol. - Anim. 28: 309–319.
51. Hellmén, E., Moller, M., Blankenstein, M. A., Andersson, L. and Westermark, B. 2000. Expression of different phenotypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. Breast Cancer Res. Treat. 61: 197– 210.
52. Hurst, E. A., Pang, L. Y. and Argyle, D. J. 2019. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet. Comp. Oncol. 17: 194–207.
53. Hymowitz, S. G., Connell, M. P. O., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., Vos, A. M. De, Kelley, R. F. and de Vos, A. M. 2000. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry. 39: 633–640.
54. Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P. and Zhou, T. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7: 954–960.
55. Johnson, A. S., Couto, C. G. and Weghorst, C. M. 1998. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis. 19: 213–217.
56. Johnson, K., Powers, B., Withrow, S., Sheetz, M., Curtis, C. and Wrigley, R. 1989. Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy. J. Vet. Intern. Med. 3: 160–166.
57. Kelley, S. K., Harris, L. A., Xie, D., Deforge, L., Totpal, K., Bussiere, J. and Fox, J. A. 2001. Preclinical studies to predict the disposition of Apo2L / tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy , pharmacokinetics , and safety. J. Pharmacol. Exp. Ther. 299: 31–38.
58. Khanna, C., Lindblad-Toh, K., Vali, D., London, C., Bergman, P., Barber, L., Matther, B., Kitchell, B., McNeil, E., Modiano, J., Niemi, S., Comstock, K. E., Ostrander, E., Westmoreland, S. and Withrow, S. 2006. The dog as a cancer model. Nat. Biotechnol. 24: 1065–1066.
59. Khemlina, G., Ikeda, S. and Kurzrock, R. 2017. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol. Cancer. 16: 1–10.
60. Kim, J.-H., Graef, A., Dickerson, E. and Modiano, J. 2015. Pathobiology of hemangiosarcoma in dogs: Research advances and future perspectives. Vet. Sci. 2: 388–405.
61. Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J. and Ashkenazi, A. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12: 611–620.
62. Kischkel, F. C., Lawrence, D. A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D. and Ashkenazi, A. 2001. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276: 46639–46646.
63. Kleine, L., Zook, B. and Munson, T. 1970. Primary cardiac hemangiosarcoma in dogs. J Am Vet Med Assoc. 157: 326–337.
64. Kodama, A., Sakai, H., Matsuura, S., Murakami, M., Murai, A., Mori, T., Maruo, K., Kimura, T., Masegi, T. and Yanai, T. 2009. Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. BMC Cancer. 9: 363.
65. Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., Keith, B. R., Gilmer, T. M., Berger, M., Podratz, K. C. and Slamon, D. J. 2006. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66: 1630–1639.
66. Koornstra, J. J., Kleibeuker, J. H., van Geelen, C. M. M., Rijcken, F. E. M., Hollema, H., de Vries, E. G. E. and de Jong, S. 2003. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. 200: 327–335.
67. Koshino, A., Goto-Koshino, Y., Setoguchi, A., Ohno, K. and Tsujimoto, H. 2016. Mutation of p53 gene and its correlation with the clinical outcome in dogs with lymphoma. J. Vet. Intern. Med. 30: 223–229.
68. Laia Solano-Gallego, C. M. 2016. Reproductive system. p. 319. In: canine an d feline cytology a color atras and interpretation guide, 3rd ed., (Rose E. Raskin, Denny J. Meyer eds.) Elsevier, St.Louis, Missouri.
69. Lauwes, G. ., Carneiro, F., Graham, D., Curado, M. P., Franceshi, S., Montgomery, E., Tatematsu, M. and Hattori, T. 2010. Tumors of the stomach. pp. 48–58. In: WHO Classification of Tumours of the Digestive System, 4th ed., (Bosman, Fred T., Carneiro, Fatima, Hruban, Ralph H. and Theise, Neil D. eds.) International Agency for Research on Cancer, Lyon.
70. LeBlanc, H. N. and Ashkenazi, A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10: 66–75.
71. Lee, S. and Margolin, K. 2011. Cytokines in cancer immunotherapy. Cancers (Basel). 3: 3856–3893.
72. Leeuwen, I. S. Van, Hellmèn, E., Cornelisse, C. J., Burgh, B. D. Van and Rutteman, G. R. 1996. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res. 16: 3737–3744.
73. Leyva, F. J., Loughin, C. A., Dewey, C. W., Marino, D. J., Akerman, M. and Lesser, M. L. 2018. Histopathologic characteristics of biopsies from dogs undergoing surgery with concurrent gross splenic and hepatic masses: 125 cases (2012-2016). BMC Res. Notes. 11: 14–18.
74. Liptak, J. M., Dernell, W. S., Monnet, E., Powers, B. E., Bachand, A. M., Kenney, J. G. and Withrow, S. J. 2004. Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002). J Am Vet Med Assoc. 225: 1225–1230.
75. Lodish, H., Berk, A., Kaiser, C. A., Krieger, M., Bretscher, A., Plogh, H., Amon, A. and Scott, M. P. 2013. Molecular cell biology. pp. 65–66. In: Molecular cell Biology, 7th ed., W. H. Freeman and company, New York.
76. Marconato, L., Romaneli, G., Stefanello, D., Giacoboni, C., Bonfanti, U., Bettini, G., Finotello, R., Verganti, S., Valenti, P., Ciaramella, L. and Zini, E. 2009. Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008). J Am Vet Med Assoc. 235: 967–972.
77. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P. and Ashkenazi, A. 1997. A novel receptor for Apo2L / TRAIL contains a truncated death domain. Curr. Biol. 7: 1003–1006.
78. Martín-Ruiz, A., Peña, L., González-Gil, A., Díez-Córdova, L. T., Cáceres, S. and Illera, J. C. 2018. Effects of indole-3-carbinol on steroid hormone profile and tumor progression in a mice model of canine inflammatory mammarycancer. BMC Cancer. 18: 10–14.
79. Matsuyama, A., Poirier, V. J., Mantovani, F., Foster, R. A. and Mutsaers, A. J. 2017. Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma. J. Am. Anim. Hosp. Assoc. 53: 304–312.
80. Mayr, B., Schaffner, W., Botto, I., Reifinger, M. and Loupal, G. 1997. Canine tumor suppressor gene p53-mutation in a case of adenoma of circumanal glands. Vet. Res. Commun. 21: 369–373.
81. Huarte, E., Fisher, J., Turk, M. J., Mellinger, D., Foster, C., Wolf, B., Meehan, K. R., Fadul, C. E. and Ernstoff, M. S. 2009. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett. 285: 80–88.
82. Menezes, M. E., Genetics, M., Bhatia, S., Genetics, M., Bhoopathi, P., Genetics, M., Das, S. K., Genetics, M., Emdad, L., Genetics, M., Dasgupta, S., Genetics, M., Dent, P., Wang, X. and Genetics, M. 2014. MDA-7/IL-24: Multifunctional cancer killing cytokine. Adv Exp Med Biol. 818: 127–153.
83. Michael H. Goldschmidt, Laura Pena, V. zappulli 2017. Tumors of the mammary gland. p. 723. In: Tumors in Domestic Animals, Fifth ed., (Meuten, Donald J. eds.) Wiley Blackwell, Ames.
84. Monzur Rahman, Sean R. Davis,Janet G. Pumphrey,Jing Bao,Marion M. Nau,Paul S. Meltzer, S. L. 2009. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat. 113: 217–230.
85. Murai, A., Asa, S. A., Kodama, A., Hirata, A., Yanai, T. and Sakai, H. 2012. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet. Res. 8: 1–14.
86. Murakami, M., Sakai, H., Kodama, A., Mori, T., Maruo, K., Yanai, T. and Masegi, T. 2008. Expression of the anti-apoptotic factors Bcl-2 and survivin in canine vascular tumours. J. Comp. Pathol. 139: 1–7.
87. Murakami, M., Sakai, H., Kodama, A., Yanai, T., Mori, T., Maruo, K. and Masegi, T. 2009. Activation of matris metalloproteinase (MMP)-2 by membrane type 1-MMP and abnormal immunolocalization of the basement membrane components laminin and type Ⅳ collagen in canine spontaneous hemangiosarcoma. Histol. Histopathol. 24: 437–446.
88. Muto, T., Wakui, S., Takahashi, H., Maekawa, S., Masaoka, T., Ushigome, S. and Furusato, M. 2000. P53 gene mutations occurring in spontaneous benign and malignant mammary tumors of the dog. Vet. Pathol. 37: 248– 253.
89. Naoum, G. E., Buchsbaum, D. J., Tawadros, F., Farooqi, A. and Arafat, W. O. 2017. Journey of TRAIL from bench to bedside and its potential role in immuno-oncology. Oncol. Rev. 11: 26–42.
90. Nóbrega, D. F., Sehaber, V. F., Madureira, R. and Bracarense, A. P. F. R. L. 2019. Canine cutaneous haemangiosarcoma: Biomarkers and survival. J. Comp. Pathol. 166: 87–96.
91. Okano, H., Shiraki, K., Inoue, H., Kawakita, T., Yamanaka, T., Deguchi, M., Sugimoto, K., Sakai, T., Ohmori, S., Fujikawa, K., Murata, K. and Nakano, T. 2003. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab. Investig. 83: 1033–1043.
92. Olsen, J. A., Thomson, M., O’Connell, K. and Wyatt, K. 2018. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Vet. Med. Sci. 4: 237–251.
93. Palacios, C., Yerbes, R. and López-Rivas, A. 2006. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 66: 8858–8869.
94. Pan, G., Ni, J., Wei, Y. F., Yu, G. I., Gentz, R. and Dixit, V. M. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (80-. ). 277: 815–818.
95. Pan, G., O’Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J. and Dixit, V. M. 1997. The receptor for the cytotoxic ligand TRAIL. Science (80-. ). 276: 111–113.
96. Paoloni, M. C. and Khanna, C. 2007. Comparative oncology today. Vet Clin North Am Small anim Pr. 37: 1023–v.
97. Pawlak A, DE Miguel D, Kutkowska J, Obmińska-Mrukowicz B, Rapak A, M.-L. L. 2017. Flavopiridol strongly sensitizes canine lymphoma cells to TRAIL-induced apoptosis. Anticancer Res. 37: 6655–6665.
98. Perez, A. M. D., Tabanera, E. and Pena, L. 2001. Inflammatory mammary carcinoma in dogs: 33 case (1995-1999). J Am Vet Med Assoc. 219: 1110– 1114.
99. Philibert, J. C., Snyder, P. W., Glickman, N., Glickman, L. T., Knapp, D. W. and Waters, D. J. 2003. Influence of host factors on survival in dogs with malignant mammary gland tumors. J. Vet. Intern. Med. 17: 102–106.
100. Pinho, S. S., Carvalho, S., Cabral, J., Reis, C. A. and Gärtner, F. 2012. Canine tumors: A spontaneous animal model of human carcinogenesis. Transl. Res. 159: 165–172.
101. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A. and Ashkenazi, A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687– 12690.
102. Premzl, M. 2016. Comparative genomic analysis of eutherian tumor necrosis factor ligand genes. Immunogenetics. 68: 125–132.
103. Prymak C, McKee LJ, Goldschmidt MH, G. L. 1988. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc. 193: 706–12.
104. PT Daniel, T wieder, I Sturm, K. S.-O. 2001. The kiss of death: Promises and failures of death receptors and ligands in cancer therapy. Leukemia. 15: 1022–1032.
105. Pukae, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, L., Von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T. and Albert, V. 2005. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer. 92: 1430–1441.
106. Queiroga, F. L., Raposo, T., Carvalho, M. I., Prada, J. and Pires, I. 2011. Canine mammary tumours as a model study human breast cancer: most recent findings. In Vivo (Brooklyn). 25: 455–465.
107. Rasotto, R., Zappulli, V., Castagnaro, M. and Goldschmidt, M. H. 2012. A retrospective study of those histopathologic parameters predictive of invasion of the lymphatic system by canine mammary carcinomas. Vet. Pathol. 49: 330–340.
108. Rasotto, R., Berlato, D., Goldschmidt, M. H. and Zappulli, V. 2017. Prognostic significance of canine mammary tumor histologic subtypes: An observational cohort study of 229 cases. Vet. Pathol. 54: 571–578.
109. Finotello, R., Stefanello,D., Zini, E. and Marconato, L. 2017. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Vet. Comp. Oncol. 15: 25– 35.
110. Rong, S., Cai, J. H. and Andrews, J. 2008. Cloning and apoptosis-inducing activities of canine and feline TRAIL. Mol. Cancer Ther. 7: 2181–2191.
111. Rossi, F., Sabattini, S., Vascellari, M. and Marconato, L. 2018. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma. Vet. Comp. Oncol. 16: 497–504.
112. Rytomaa Marjatta, Martins L. Miguel, D. J. 1999. Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis. Curr. Biol. 9: 1043–1046.
113. Sato, M., Kanemoto, H., Kagawa, Y., Kobayashi, T., Goto-Koshino, Y., Mochizuki, H., Takahashi, M., Fujino, Y., Ohno, K. and Tsujimoto, H. 2012. Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma. Vet. J. 191: 108–114.
114. Schiffman, J. D. and Breen, M. 2015. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos. Trans. R. Soc. B Biol. Sci. 370: 1–13.
115. Schneider, P., Bodmer, J. L., Thome, M., Hofmann, K., Holler, N. and Tschopp, J. 1997. Characterization of two receptors for TRAIL. FEBS Lett. 416: 329–334.
116. Schultheiss, P. C. 2004. A retrospective study of visceral and nonvisceral HSA and hemangiomas in domestic animals. J. Vet. Diagnostic Investig. 16: 522–526.
117. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P. and Ashkenazi, A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277: 818–821.
118. Simonet, W. ., Lacey, D. ., Dunstan, C. ., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. ., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.-L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. ., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. and Boyle, W. . 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 89: 309–319.
119. Singh, T. R., Shankar, S. and Srivastava, R. K. 2005. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 24: 4609–4623.
120. Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C., Gadgeel, S. M., Riely, G. J., Tan, E. H., Seto, T., James, L. P., Clancy, J. S., Abbattista, A., Martini, J., Chen, J., Peltz, G. and Thurm, H. 2018. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19: 1654–1667.
121. Sorenmo, K. U., Worley, D. R. and Goldschmidt, M. H. 2013. Tumors of the Mammary Gland. pp. 538–547. In: Withrow and Masewen’s small animal clinical oncology, 5th ed., (Withrow, Stephen J., Vail, David M. and Page, Rodney L. eds.) Elsevier saunders, St.Louis.
122. Spangler WL, C. M. 1992. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989). J Am Vet Med Assoc. 200: 829–34.
123. Spee, B., Jonkers, M. D. B., Arends, B., Rutteman, G. R., Rothuizen, J. and Penning, L. C. 2006. Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol. Cancer. 5: 1–10.
124. Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H. and Walczak, H. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 12: 599–609.
125. Srivastava, R. K., Kurzrock, R. and Shankar, S. 2010. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol. Cancer Ther. 9: 3254–3266.
126. Stephan, L. and Jermy, B. 1994. Principles of bioinorganic chemistry, 1st ed., pp.44-46. Unicersity Science Books, California.
127. Stoklasek, T. A., Schluns, K. S. and Lefrançois, L. 2006. Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177: 6072–6080.
128. Szczubiał, M. and Łopuszynski, W. 2011. Prognostic value of regional lymph node status in canine mammary carcinomas. Vet. Comp. Oncol. 9: 296–303.
129. Takeda, K., Stagg, J., Yagita, H., Okumura, K. and Smyth, M. J. 2007. Targeting death-inducing receptors in cancer therapy. Oncogene. 26: 3745– 3757.
130. Tamura, D., Saito, T., Murata, K., Kawashima, M. and Asano, R. 2015. Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms. Int. J. Oncol. 46: 1393–1404.
131. Tolcher, A. W., Mita, M., Meropol, N. J., Von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., Halpern, W., Corey, A. and Cohen, R. B. 2007. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25: 1390–1395.
132. Tran, C. M., Moore, A. S. and Frimberger, A. E. 2016. Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy. Vet. Comp. Oncol. 14: 252–262.
133. Trarbach, T., Moehler, M., Heinemann, V., Köhne, C. H., Przyborek, M., Schulz, C., Sneller, V., Gallant, G. and Kanzler, S. 2010. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer. 102: 506–512.
134. Trivedi, R. and Mishra, D. P. 2015. Trailing TRAIL resistance: Novel targets for TRAIL sensitization in cancer cells. Front. Oncol. 5: 1–20.
135. Valli VE, Bienzle D, Meuten DJ, L. K. 2017. Tumors of hemolymphatic system. pp. 309–313. In: Tumor in Domestinc Animals, 5th ed., (DJ, Meuten eds.) Wiley Blackwell, Ames.
136. Veldhoen, N., Stewart, J., Brown, R. and Milner, J. 1998. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene. 16: 249–255.
137. Vousden, K. H. and Lu, X. 2002. Live or let die: The cell’s response to p53. Nat. Rev. Cancer. 2: 594–604.
138. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C. and Lynch, D. H. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157–163.
139. Walczak, H., Degli-esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G. and Rauch, C. T. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386–5397.
140. Wang, X., Simpson, E. R. and Brown, K. A. 2015. p53: Protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 75: 5001–5007.
141. Wawryk-Gawda, E., Chylińska-Wrzos, P., Lis-Sochocka, M., Chłapek, K., Bulak, K., Jędrych, M. and Jodłowska-Jędrych, B. 2014. P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 251: 525–533.
142. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A. and Goodwin, R. G. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3: 673–82.
143. Xu, W., Jones, M. onica, Liu, B., Zhu, X., Johnson, C. B., Edwards, A. C., Kong, L., Jeng, E. K., Han, K., Marcus, W. D., Rubinstein, M. P., Rhode, P. R. and Wong, H. C. 2013. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73: 3075– 3086.
144. Yonemaru, K., Sakai, H., Murakami, M., Kodama, A., Mori, T., Yanai, T., Maruo, K. and Masegi, T. 2007. The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma. J. Vet. Med. Sci. 69: 271–278.
145. Yonemaru, K., Sakai, H., Murakami, M., Yanai, T. and Masegi, T. 2006. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors ( Flt-1, Flk-1, and Flg-1 ) in canine vascular tumors. Vet Pathol. 980: 971–980.
146. Zandvliet, M. 2016. Canine lymphoma: a review. Vet. Q. 36: 76–104.
147. Zhang, H., Pei, S., Zhou, B., Wang, H., Du, H., Zhang, D. and Lin, D. 2018. Establishment and characterization of a new triple-negative canine mammary cancer cell line. Tissue Cell. 54: 10–19.
148. Zhang, L. and Fang, B. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12: 228–237.
論文の公開元へ
